Kyfil 30 mg contains carfilzomib, a targeted anti-cancer medication used in the treatment of multiple myeloma, a type of cancer that forms in plasma cells of the bone marrow. It belongs to a class of drugs called proteasome inhibitors, which specifically block certain protein complexes that cancer cells depend on to grow and survive.

Carfilzomib is typically used in patients who have already received other treatments and may be administered in combination with other medicines like lenalidomide and dexamethasone. It is given as an intravenous infusion under the supervision of a healthcare provider.

Mechanism of Action

Carfilzomib works by inhibiting the proteasome, a protein complex inside cells that breaks down unwanted or damaged proteins. In cancer cells, this function is especially important because their rapid growth leads to the buildup of abnormal proteins.

By blocking the proteasome, carfilzomib causes a buildup of these defective proteins, which interferes with vital cellular processes and leads to cancer cell stress and death. Normal cells are less dependent on this pathway, so the drug preferentially targets cancer cells.

Uses

Kyfil is primarily used in the treatment of relapsed or refractory multiple myeloma, which means the disease has returned after or is resistant to previous treatment. It is often prescribed as part of a combination regimen and may be used with other drugs like:

• Lenalidomide and dexamethasone

• Dexamethasone alone, for patients who may not tolerate additional medications

The choice of combination depends on the patient’s condition, treatment history, and tolerance to previous therapies.

Adverse Effects

As with most anti-cancer treatments, carfilzomib can cause side effects, some of which may be serious and require close monitoring.

Common Side Effects

• Fatigue or weakness

• Low blood cell counts, especially white cells and platelets

• Nausea and vomiting

• Fever and flu-like symptoms

• Shortness of breath

• Diarrhoea or constipation